Department of Medical Microbiology, Sanko University School of Medicine, Gaziantep, Turkey.
Department of Biostatistics, Sanko University School of Medicine, Gaziantep, Turkey.
J Med Virol. 2021 Sep;93(9):5560-5567. doi: 10.1002/jmv.27098. Epub 2021 May 31.
Quantitation of antibodies to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was performed for the detection of adaptive immune response in healthcare workers (HCWs) vaccinated with CorovaVac. We prospectively recruited HCWs from a university hospital in Turkey. Serum samples from 1072 HCWs were obtained following 28 days of the first, and 21 days of the second dose. Detection and quantitation of SARS-CoV-2 antispike antibodies were performed by the chemiluminescent microparticle immunoassay (SARS-CoV-2 IgG II Quant; Abbott). Results greater than or equal to the cutoff value 50.0 AU/ml were reported as positive. After the first dose, antispike antibodies were detected in 834 of 1072 (77.8%) HCWs. Seropositivity was higher among females (84.6%) than males (70.6%) (p < 0.001) and was found to be highest in both women and men between the ages of 18-34. After the second dose, antibodies were detected in 1008 of 1012 (99.6%) HCWs. Antibody titers were significantly higher in those who had coronavirus disease-2019 before vaccination than those who did not (p < 0.001). Antibody positivity and median antibody titers were significantly less in HCWs with chronic diseases compared to those without (p < 0.05 and p < 0.001, respectively). In conclusion, our findings indicated that a relatively high frequency (99.6%) of humoral immunity was produced in HCWs aged 18-59 after two doses of CoronaVac. Quantitation of antibodies may help facilitate longitudinal monitoring of the antibody response, which will be especially useful in deciding the dose of the vaccine in vulnerable groups such as those over 60 years of age and those with chronic diseases.
对 1072 名医护人员（HCWs）在接种科瓦克疫苗 28 天后的第 1 针和 21 天后的第 2 针采集血清样本，检测和定量 SARS-CoV-2 刺突蛋白抗体。采用化学发光微粒子免疫分析（SARS-CoV-2 IgG II Quant；雅培）检测 SARS-CoV-2 抗刺突抗体。报道结果大于或等于截值 50.0 AU/ml 为阳性。第 1 针后，在 1072 名 HCWs 中的 834 名（77.8%）检测到抗刺突抗体。女性（84.6%）的血清阳性率高于男性（70.6%）（p < 0.001），18-34 岁的男女血清阳性率最高。第 2 针后，在 1012 名 HCWs 中的 1008 名（99.6%）检测到抗体。接种疫苗前患有 COVID-19 的人的抗体滴度明显高于未患 COVID-19 的人（p < 0.001）。与无慢性病的 HCWs 相比，有慢性病的 HCWs 的抗体阳性率和中位数抗体滴度明显较低（p < 0.05 和 p < 0.001）。总之，我们的研究结果表明，在 18-59 岁的 HCWs 中，两剂科瓦克疫苗后产生了相对较高频率（99.6%）的体液免疫。抗体定量可能有助于对抗体反应进行纵向监测，这在决定 60 岁以上和患有慢性病等弱势群体的疫苗剂量方面尤其有用。
